{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
US Approved Rx
(2002)
Source:
ANDA076350
(2002)
Source URL:
First marketed in 1921
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Possibly Marketed Outside US
Source:
21 CFR 348
(2016)
Source URL:
First approved in 2016
Source:
21 CFR 348
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Possibly Marketed Outside US
First approved in 2011
Source:
21 CFR 333E
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Morpholine salicylate is a derivative of salicylic acid. It is a non-steroidal anti-inflammatory drug and was marketed under a tradename Retarcyl, Dolical and Deposal.
Status:
US Approved Rx
(2002)
Source:
ANDA076350
(2002)
Source URL:
First marketed in 1921
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
US Approved Rx
(2002)
Source:
ANDA076350
(2002)
Source URL:
First marketed in 1921
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
US Approved Rx
(2002)
Source:
ANDA076350
(2002)
Source URL:
First marketed in 1921
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
US Approved Rx
(2002)
Source:
ANDA076350
(2002)
Source URL:
First marketed in 1921
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
US Approved Rx
(2002)
Source:
ANDA076350
(2002)
Source URL:
First marketed in 1921
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
US Approved Rx
(2002)
Source:
ANDA076350
(2002)
Source URL:
First marketed in 1921
Class (Stereo):
CHEMICAL (ACHIRAL)
